drugset
drugset / Trial / NCT00320398

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

NCT00320398 ↗

Phase 3 Completed 114 enrolled GlaxoSmithKline
RandomizedParallel-groupPrevention

Summary

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

Timeline

Start
2006-01-30
Primary completion
2006-07-18
Completion
2006-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Fondaparinux Other / unclassified — —

Indications

venous thromboembolism